Monopar Therapeutics — Third Quarter 2026 Earnings Summary

Monopar Therapeutics reported a net loss of $6.2 million for the third quarter of 2026, with cash and investments totaling $129.4 million sufficient to fund operations through March 31, 2028. The company initiated a rolling New Drug Application submission to the FDA for ALXN1840, a first-in-class treatment for Wilson disease, and appointed Jeffrey D. Kent as Executive Vice President of Medical Affairs. Financial results showed increased research and development expenses driven by contractor and personnel costs, while interest income rose due to higher cash balances from a prior capital raise.